Targeting the eukaryotic translation initiation factor 4E for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in human cancers, correlating with disease progression.
• Enhanced eIF4E activity drives cellular transformation, tumorigenesis, and metastasis.
• eIF4E overexpression or pathway activation (Ras, PI3K/AKT) increases translation of mRNAs crucial for tumor growth, angiogenesis, and survival.

Purpose of the Study:

• To evaluate the therapeutic potential of targeting eIF4E in cancer treatment.
• To demonstrate the selective vulnerability of tumor cells to eIF4E inhibition.

Main Methods:

• Investigated the role of eIF4E in cancer progression and transformation.
• Assessed the efficacy of eIF4E-specific inhibition as a therapeutic strategy.
• Advanced the first eIF4E-specific therapy into clinical trials.

Main Results:

• Targeting eIF4E can simultaneously reduce the expression of multiple malignancy-driving factors.
• Tumor tissues exhibit increased susceptibility to eIF4E inhibition.
• The first eIF4E-specific therapy has progressed to clinical trials.

Conclusions:

• Therapeutic targeting of eIF4E is a plausible strategy for treating various cancer types.
• Enhanced eIF4E function, common in many tumors, represents a potential Achilles' heel for cancer.
• eIF4E inhibition offers a novel approach to selectively reduce tumor growth and survival factors.